Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Cancer Supportive Care Drugs Market, Therapeutic Class
7.1. Cancer Supportive Care Drugs Market, Therapeutic Class, 2020-2028
7.1.1. G-CSFs (Granulocyte-colony Stimulating Factors)
7.1.1.1. Market Revenue and Forecast (2016-2028)
7.1.2. ESAs (Erythropoiesis Stimulating Agents)
7.1.2.1. Market Revenue and Forecast (2016-2028)
7.1.3. Anti-emetics
7.1.3.1. Market Revenue and Forecast (2016-2028)
7.1.4. Bisphosphonates
7.1.4.1. Market Revenue and Forecast (2016-2028)
7.1.5. Opioids
7.1.5.1. Market Revenue and Forecast (2016-2028)
7.1.6. NSAIDs
7.1.6.1. Market Revenue and Forecast (2016-2028)
Chapter 8. Global Cancer Supportive Care Drugs Market, Regional Estimates and Trend Forecast
8.1. North America
8.1.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.1.2. U.S.
8.1.3. Rest of North America
8.1.3.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.2. Europe
8.2.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.2.2. UK
8.2.2.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.2.3. France
8.2.3.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.2.4. Rest of Europe
8.2.4.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.3. APAC
8.3.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.3.2. India
8.3.2.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.3.3. China
8.3.3.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.3.4. Japan
8.3.4.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.3.5. Rest of APAC
8.3.5.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.4. MEA
8.4.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.4.2. GCC
8.4.2.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.4.3. North Africa
8.4.3.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.4.4. South Africa
8.4.4.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.4.5. Rest of MEA
8.4.5.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.5. Latin America
8.5.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.5.2. Brazil
8.5.2.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
8.5.3. Rest of LATAM
8.5.3.1. Market Revenue and Forecast, Therapeutic Class (2016-2028)
Chapter 9. Company Profiles
9.1. Amgen
9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. Johnson & Johnson
9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. Merck
9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. Roche
9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
9.5. Helsinn Healthcare
9.5.1. Company Overview
9.5.2. Product Offerings
9.5.3. Financial Performance
9.5.4. Recent Initiatives
9.6. Heron Pharma
9.6.1. Company Overview
9.6.2. Product Offerings
9.6.3. Financial Performance
9.6.4. Recent Initiatives
9.7. Tesaro
9.7.1. Company Overview
9.7.2. Product Offerings
9.7.3. Financial Performance
9.7.4. Recent Initiatives
Chapter 10. Research Methodology
10.1. Primary Research
10.2. Secondary Research
10.3. Assumptions
Chapter 11. Appendix
11.1. About Us
Glossary of Terms